Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus
— Clinical Proof-of-Concept Data Expected in Second Half of 2019 — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Dicerna Pharmaceuticals, Inc . (NASDAQ: DRNA), (the “Company”) a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer...
View HTML
Toggle Summary Dicerna Evolves Its Board of Directors to Support Continued Growth
— J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board — — Company Thanks Departing Chairman David Madden and Director Brian Halak — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- Dicerna Pharmaceuticals, Inc....
View HTML
Toggle Summary Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2019-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019 , the Compensation Committee of the Company's Board of Directors...
View HTML
Toggle Summary Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) INGELHEIM, Germany & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Boehringer Ingelheim  and  Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA...
View HTML
Toggle Summary Dicerna to Join NASDAQ Biotechnology Index
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 20, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the...
View HTML
Toggle Summary Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and...
View HTML
Toggle Summary Dicerna to Participate in Citi’s 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 29, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will host one-on-one...
View HTML
Toggle Summary Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018
Live Webcast to Begin at 8:30 a.m. Eastern Time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to discuss its...
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in...
View HTML
Toggle Summary Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019 Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna’s GalXC™ Technology Platform Closed $115.0 Million Financing...
View HTML